Matthew L. Crawley
Incyte
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Matthew L. Crawley.
Journal of Medicinal Chemistry | 2010
Joseph T. Lundquist; Douglas C. Harnish; Callain Younghee Kim; John F. Mehlmann; Rayomand J. Unwalla; Kristin M. Phipps; Matthew L. Crawley; Thomas Joseph Commons; Daniel M. Green; Weixin Xu; Wah-Tung Hum; Julius E. Eta; Irene Feingold; Vikram S. Patel; Mark J. Evans; KehDih Lai; Lisa Borges-Marcucci; Paige Erin Mahaney; Jay E. Wrobel
In an effort to develop orally active farnesoid X receptor (FXR) agonists, a series of tetrahydroazepinoindoles with appended solubilizing amine functionalities were synthesized. The crystal structure of the previously disclosed FXR agonist, 1 (FXR-450), aided in the design of compounds with tethered solubilizing functionalities designed to reach the solvent cavity around the hFXR receptor. These compounds were soluble in 0.5% methylcellulose/2% Tween-80 in water (MC/T) for oral administration. In vitro and in vivo optimization led to the identification of 14dd and 14cc, which in a dose-dependent fashion regulated low density lipoprotein cholesterol (LDLc) in low density lipoprotein receptor knockout (LDLR(-/-)) mice. Compound 14cc was dosed in female rhesus monkeys for 4 weeks at 60 mg/kg daily in MC/T vehicle. After 7 days, triglyceride (TG) levels and very low density lipoprotein cholesterol (VLDLc) levels were significantly decreased and LDLc was decreased 63%. These data are the first to demonstrate the dramatic lowering of serum LDLc levels by a FXR agonist in primates and supports the potential utility of 14cc in treating dyslipidemia in humans beyond just TG lowering.
Journal of Biological Chemistry | 2006
Paul J. Ala; Lucie Gonneville; Milton Hillman; Mary Becker-Pasha; Eddy W. Yue; Brent Douty; Brian Wayland; Padmaja Polam; Matthew L. Crawley; Erin McLaughlin; Richard B. Sparks; Brian Glass; Amy Takvorian; Andrew P. Combs; Timothy C. Burn; Gregory F. Hollis; Richard Wynn
Structural analyses of the protein-tyrosine phosphatase 1B (PTP1B) active site and inhibitor complexes have aided in optimization of a peptide inhibitor containing the novel (S)-isothiazolidinone (IZD) phosphonate mimetic. Potency and permeability were simultaneously improved by replacing the polar peptidic backbone of the inhibitor with nonpeptidic moieties. The C-terminal primary amide was replaced with a benzimidazole ring, which hydrogen bonds to the carboxylate of Asp48, and the N terminus of the peptide was replaced with an aryl sulfonamide, which hydrogen bonds to Asp48 and the backbone NH of Arg47 via a water molecule. Although both substituents retain the favorable hydrogen bonding network of the peptide scaffold, their aryl rings interact weakly with the protein. The aryl ring of benzimidazole is partially solvent exposed and only participates in van der Waals interactions with Phe182 of the flap. The aryl ring of aryl sulfonamide adopts an unexpected conformation and only participates in intramolecular π-stacking interactions with the benzimidazole ring. These results explain the flat SAR for substitutions on both rings and the reason why unsubstituted moieties were selected as candidates. Finally, substituents ortho to the IZD heterocycle on the aryl ring of the IZD-phenyl moiety bind in a small narrow site adjacent to the primary phosphate binding pocket. The crystal structure of an o-chloro derivative reveals that chlorine interacts extensively with residues in the small site. The structural insights that have led to the discovery of potent benzimidazole aryl sulfonamide o-substituted derivatives are discussed in detail.
Bioorganic & Medicinal Chemistry Letters | 2009
John F. Mehlmann; Matthew L. Crawley; Joseph T. Lundquist; Ray Unwalla; Douglas C. Harnish; Mark J. Evans; Callain Younghee Kim; Jay E. Wrobel; Paige Erin Mahaney
Pyrrole[2,3-d]azepines have been identified as potent agonists of the farnesoid X receptor (FXR). Based on the planar X-ray crystal structure of WAY-362450 1 in the ligand binding domain and molecular modeling studies, non-planar reduced compounds were designed which led to agonists that exhibit high aqueous solubility and retain moderate in vitro potency.
Organic Letters | 2009
Matthew L. Crawley; Kristin M. Phipps; Igor Goljer; John F. Mehlmann; Joseph T. Lundquist; John W. Ullrich; Cuijian Yang; Paige Erin Mahaney
An efficient and mild method to couple aryl bromides and activated non-allylic alcohols in a Heck reaction with tandem isomerization to selectively afford high yields of 1,5-diarylalkan-1-ones has been developed. Mechanistic insight was gained through NMR studies of products derived from deuterium-labeled intermediates.
Journal of Medicinal Chemistry | 2005
Andrew P. Combs; Eddy W. Yue; Michael J. Bower; Paul J. Ala; Brian Wayland; Brent Douty; Amy Takvorian; Padmaja Polam; Zelda R. Wasserman; Wenyu Zhu; Matthew L. Crawley; James Russell Pruitt; Richard B. Sparks; Brian Glass; Dilip P. Modi; Erin McLaughlin; Lori L. Bostrom; Mei Li; Laurine Galya; Karl F. Blom; Milton Hillman; Lucie Gonneville; Brian G. Reid; Min Wei; Mary Becker-Pasha; Ronald M. Klabe; Reid Huber; Yanlong Li; Gregory F. Hollis; Timothy C. Burn
Journal of Medicinal Chemistry | 2006
Andrew P. Combs; Wenyu Zhu; Matthew L. Crawley; Brian Glass; Padmaja Polam; Richard B. Sparks; Dilip P. Modi; Amy Takvorian; Erin McLaughlin; Eddy W. Yue; Zelda R. Wasserman; Michael J. Bower; Min Wei; Mark Rupar; Paul J. Ala; Brian M. Reid; Dawn Ellis; Lucie Gonneville; Thomas Emm; Nancy Taylor; Swamy Yeleswaram; Yanlong Li; Richard Wynn; Timothy C. Burn; Gregory F. Hollis; Phillip Liu; Brian Walter Metcalf
Archive | 2005
James D. Rodgers; Darius J. Robinson; Argyrios G. Arvanitis; Thomas Maduskuie; Stacey Shepard; Louis Storace; Haisheng Wang; Maria Rafalski; Ravi Kumar Jalluri; Andrew P. Combs; Matthew L. Crawley
Organic Letters | 2006
Matthew L. Crawley; Igor Goljer; Douglas John Jenkins; John F. Mehlmann; Lisa M. Nogle; Rebecca Dooley; Paige Erin Mahaney
Bioorganic & Medicinal Chemistry Letters | 2007
Richard B. Sparks; Padmaja Polam; Wenyu Zhu; Matthew L. Crawley; Amy Takvorian; Erin McLaughlin; Min Wei; Paul J. Ala; Lucie Gonneville; Nancy Taylor; Yanlong Li; Richard Wynn; Timothy C. Burn; Phillip C.C. Liu; Andrew P. Combs
Bioorganic & Medicinal Chemistry | 2006
Eddy W. Yue; Brian Wayland; Brent Douty; Matthew L. Crawley; Erin McLaughlin; Amy Takvorian; Zelda R. Wasserman; Michael J. Bower; Min Wei; Yanlong Li; Paul J. Ala; Lucie Gonneville; Richard Wynn; Timothy Burn; Phillip Liu; Andrew P. Combs